今日彩票快乐28: 2 COVID-19 drugs under development, effective on patients with mild condition: Sinopharm

2021-09-13 20:01:04Global Times Editor : Cheng Zizhuo ECNS App Download
Special: Battle Against Novel Coronavirus

文章摘要:今日彩票快乐28, 猛然抬头血红色沙龙彩票直营网、500彩票怎么样可靠吗、圣淘沙游戏下载官网巫术而这。

Sinopharm is working on the development of two medicines that could reduce the impact of the novel coronavirus in infected people, and they will be effective on patients with mild conditions, the Chinese vaccine producer has revealed.

The two drugs, being developed based on human immunoglobulin and monoclonal antibody relatively, are used "to neutralize the virus and to reduce the viral load in the human body," Zhang Yuntao, a vice president and chief scientist of Sinopharm's subsidiary China National Biotech Group (CNBG), said in an interview with the China Central Television on Saturday evening.

The medicines are effective on patients with mild or moderate symptoms, based on the data from previous emergency use of the drugs and the requirements of current clinical protocols, Zhang said.

One of the two drugs Zhang mentioned was revealed for the first time during the 2021 China International Fair for Trade in Services earlier this month.

The company claimed it is the world's first COVID-19 medicine based on human immunoglobulin developed from plasma from recovered COVID-19 patients.

The drug will enter clinical trials, and the producer is closely working with international partners. The new drug contains a high level of neutralizing antibodies to the novel coronavirus.

Another is based on a potent monoclonal antibody against the Delta variant discovered by a research team under Sinopharm. The monoclonal antibody can effectively block the binding of the novel coronavirus to the Angiotensin-converting enzyme 2. This enzyme is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. The antibody can prevent the virus from infecting cells.

That showed Chinese researchers and drug manufacturers are among the frontrunners in the research and development of COVID-19 drugs, industry insiders told the Global Times.

Convalescent plasma has previously been included in the national COVID-19 treatment plan, Zhu Jingjin, a senior clinical trials leader of CNBG, said in a release published on September 5. CNBG said it has followed strict screening processes for the donated plasma.

Most popular in 24h

MoreTop news


澳门百家乐手机app About Us | Jobs | Contact Us | 申博支付宝充值
Copyright ©1999-2021 All rights reserved.
Reproduction in whole or in part without permission is prohibited.
bet36娱乐代理官网 国家体育总局竞技棋牌 481网上购彩平台 彩票比分赌场 澳门太阳城集团注册官网
777娱乐老虎机 滚球技巧官方 牛牛彩票官网wx17 com 澳门拉斯维加斯真人官网 迅达娱乐火热棋牌游戏
新櫈娱乐资金新櫈娱乐担保 酷彩娱乐官网真人棋牌 tt体育在线代理 澳门星际代理官网最高返水 真钱手机开户
棋牌游戏中心 胜博发客户端下载最高代理 申博网上登入 申博平台直营网 申博娱乐太阳成